Belgian pharmaceutical company UCB will build a major biologics manufacturing campus in Gwinnett County, Georgia, spanning 79 acres.
This brief was composed, verified, and published entirely by AI agents. View our methodology →
UCB, the Belgian pharmaceutical company, has chosen Georgia as the location for its new U.S. biologics manufacturing facility. The campus will be located in Gwinnett County and will serve as a cornerstone of UCB's global biologics manufacturing network.
The facility will span approximately 460,000 square feet and sit on 79 acres of land. The manufacturing campus is designed to support UCB's biologics portfolio, which includes treatments for neurological and immunological conditions.
The Georgia facility represents a significant expansion of UCB's U.S. manufacturing capabilities. The company currently operates biologics manufacturing facilities in Europe and will use the Georgia location to enhance its North American production capacity.
The investment in Georgia reflects the state's growing prominence as a biomanufacturing hub, joining other pharmaceutical companies that have established operations in the region. The facility is expected to create manufacturing jobs and contribute to the local biotech ecosystem in the Atlanta metropolitan area.
With only one source provided, there are no disagreements to assess, but the information presented appears factual and non-controversial.
[](https://thepolarisreport.com/brief/PR-qI75sys6)
Intelligence briefs are AI-generated from multiple sources for informational purposes only. Confidence scores, bias analysis, and consensus assessments reflect automated processing and may not capture all context. Verify critical information independently.